¶ÌÁ´Ö¬·¾Ëá(Short-Chain Fatty Acids, SCFAs)£¬Ò²³Æ»Ó·¢ÐÔÖ¬·¾Ëá(Volatile Fatty Acid, VFA)£¬Æ¾Ö¤Ì¼Á´ÖÐ̼Ô×ÓÊýÄ¿£¬°Ñ̼Ô×ÓÊý1-6µÄÓлúÖ¬·¾Ëá³ÆΪ¶ÌÁ´Ö¬·¾ËᣬÖ÷Òª°üÀ¨ÒÒËá¡¢±ûËá¡¢¶¡Ëá¡¢Ò춡Ëá¡¢ÎìËá¡¢ÒìÎìËá¡£
Ö÷ҪȪԴÓڽ᳦ÖÐÑáÑõϸ¾ú¶Ô³¦µÀÄÚÏËάºÍ²»¿ÉÏû»¯Ìǵķ¢½Í£¬ÊÜ·¢½Íµ×Îϸ¾úÖÖÀàµÈÒòËصÄÓ°Ï죬³¦µÀÄÚËù±¬·¢µÄ¶ÌÁ´Ö¬·¾ËáµÄÖÖÀàºÍÊýÄ¿²î±ð£¬ÆäÊ©Õ¹µÄ×÷ÓÃÒ²²»¾¡Ïàͬ¡£×÷Ϊ³¦µÀ΢ÉúÎïµÄÖ÷Òª´úл²úÆ·£¬¾ßÓÐΪ¶¯ÎïÌåÌṩÄÜÁ¿¡¢µ÷ÀíÄÜÁ¿´úл¡¢¼ÓÈëÐźÅתµ¼¡¢¸ÄÉÆÐÄѪ¹Ü¼²²¡¡¢»º½âÌÇÄò²¡²¡Ö¢¡¢Î¬³Ö³¦µÀ´úлÍêÕûÐÔ¡¢µ÷Àí³¦µÀ¾úȺºÍÃâÒß¹¦Ð§µ÷¿ØµÈ¶àÖÖÉúÎïѧ¹¦Ð§¡£
ÔÚÖ²ÎïÌåÄÚ£¬¶ÌÁ´Ö¬·¾ËáÊÇÖ÷ÒªµÄ·çÔÏÎïÖʼ°ÓªÑøÎïÖÊ£¬ÈçÑ̲ݵÄÏãζÖÐÆðÖ÷Òª×÷ÓÃ;ÔÚ¶¯ÎïÖУ¬¶ÌËá¿ÉÒÔÌá¸ßÈÑÉïĸÖíµÄ²ÉʳÁ¿Ó벸ÈéĸÖíµÄÃÚÈéÁ¿£¬½ø¶øÌá¸ßĸÖíµÄÉú²úÐÔÄÜ£¬ÔÚÇà´¢ËÇÁÏÖУ¬ÒÒËáºÍ±ûËáÖ÷Òª±»ÓÃ×÷·À¸¯¼Á¾ÙÐÐÖü´æºÍ±£ÏÊ£¬ÒÒËáµÈ¶ÌÁ´Ö¬·¾ËẬÁ¿Ó°ÏìËÇÁÏÊÊ¿ÚÐÔ¼°Ò×Ïû»¯ÎüÊÕµÄˮƽ¡£
¶ÌÁ´Ö¬·¾Ëá¼ì²âÁбí
½ÓÄÉÄڱ귨¶¨Á¿£¬¶¨ÐÔ¶¨Á¿Ð§¹û¸ü×¼
? Ñù±¾ÒªÇó
Ö²Îï×éÖ¯£º200 mg/sample
¶¯Îï¼°ÁÙ´²×éÖ¯Ñù±¾£º200 mg/sample
ѪÇ塢Ѫ½¬£º200 ¦ÌL/sample
ÄòÒº£º200 ¦ÌL/sample
ϸ°û¡¢Î¢ÉúÎ1X107cells/sample
·à±ã¡¢³¦µÀÄÚÈÝÎ200 mg/sample
? ¼ì²âƽ̨
GC-MS QP2020, Shimadzu
? ͨÀýÏîÄ¿ÖÜÆÚ
ʵÑé¼ì²â£º20¸ö×ÔÈ»ÈÕ£¨´ÓÊÕµ½¿Í»§Ô¤¸¶¿î²¢ÊÕµ½ÑùÆ·Ö®ÈÕÆð£©
Êý¾ÝÆÊÎö£º5¸ö×ÔÈ»ÈÕ
- Ò©Îï»ò±£½¡Æ·µÄ¿ª·¢Ñо¿
- ¼²²¡µÄÔçÆÚÕï¶Ï±ê¼ÇÎï·¢Ã÷Ñо¿
- Ö²Îï·çÔÏÑо¿
- ÐóÇÝËÇÁÏÖÐÌí¼Ó
? ÅÁ½ðɲ¡»¼Õß·à±ãºÍѪ½¬¶ÌÁ´Ö¬·¾ËáˮƽÓ볦µÀ¾úȺºÍÁÙ´²Ö¸±êµÄ¹Øϵ
Ñо¿¹¤¾ß: ÈËÆÚ¿¯: Neurology
Ó°ÏìÒò×Ó: 11.8
ʱ¼ä: 2022Äê
ÅÁ½ðɲ¡(Parkinson's disease, PD)ÊÇÒ»ÖÖ³£¼ûµÄÉñ¾ÏµÍ³¼²²¡¡£Ñо¿Åú×¢£¬Î¸³¦µÀÖ¢×´¿ÉÄܱÈÔ˶¯Ö¢×´Ô缸ʮÄê¡£Ó뿵½¡ÈËȺÏà±È£¬PD»¼Õß¾ßÓÐÆæÒìµÄ³¦µÀ΢ÉúÎïȺ½á¹¹£¬²¢ÇÒ³¦µÀ΢ÉúÎïȺµÄת±äÓë¼²²¡µÄÑÏÖØˮƽºÍÏ£ÍûÏà¹Ø¡£¶ÌÁ´Ö¬·¾Ëá(Short-Chain Fatty Acids, SCFAs)Êdz¦µÀ¾úȺ·¢½ÍÉÅʳÏËά±¬·¢µÄÖ÷Òª´úлÎÍƲâÔÚ³¦-ÄÔÏ໥×÷ÓÃÖÐÆðÒªº¦×÷Óᣵ«ÏÖÔÚÈÔȱ·¦¹ØÓÚ¼ì²â·à±ãºÍѪ½¬ÖÐSCFAsˮƽµÄ×ÛºÏÑо¿¡£
? Ñо¿Ð§¹û
ʹÓÃÆøÏàÉ«Æ×-ÖÊÆ×(Gas Chromatography-Mass Spectrometry, GC-MS)¶Ô·à±ãºÍѪ½¬ÖеÄSCFAs¾ÙÐж¨Á¿ÆÊÎö£¬·¢Ã÷PD»¼Õß·à±ãºÍѪ½¬ÖжÌËá±£´æ²î±ð¡£SCFAsÓëÔ˶¯ÕÏ°ÑÏÖØˮƽ¡¢ÈÏÖªÄÜÁ¦¡¢³¦µÀ¾úȺ¹ØÁªÆÊÎöÏÔʾ£¬·à±ãÖеÍˮƽSCFAs¡¢Ñª½¬Öиßˮƽ±ûËáÓëPD»¼ÕߵĵÍÔ˶¯ÄÜÁ¦Ïà¹Ø£»·à±ãÖеÍˮƽSCFAs¡¢Ñª½¬Öиßˮƽ¶¡ËáºÍÎìËáÓë½Ï²îµÄÈÏÖªÏà¹Ø£»PD»¼Õß²¿·Ö¾úȺƷòµÄ¸Ä±äÓëѪ½¬ºÍ·à±ãÖÐSCFAsˮƽÏà¹Ø¡£Ð§¹ûÅú×¢£¬SCFAs¿ÉÒÔ×÷Ϊ·´Ó¦PDÑÏÖØˮƽµÄ±ê¼ÇÎÓÐÖúÓÚ½øÒ»²½ÆÊÎöPD»¼ÕßÖØ´óµÄ³¦-ÄÔÏ໥×÷Óá£
? Ñо¿Ë¼Ð÷
? Ч¹ûչʾ
ͨ¹ý¶Ô·à±ãÓëѪ½¬ÖеÄSCFAs¼ì²â£¬·¢Ã÷Óë±ÈÕÕ×éÏà±È£¬PD»¼Õß·à±ãÖÐÒÒËá¡¢±ûËáºÍ¶¡ËáŨ¶ÈÏÔÖø½µµÍ£¨Í¼1£©£»Ñª½¬ÖбûËá¡¢¶¡ËáºÍÎìËáµÄŨ¶ÈÏÔÖøÔöÌí£¨Í¼2£©¡£
ͨ¹ýROCÇúÏßÆÊÎöÕ¹ÍûPDµÄ±¬·¢£¬·¢Ã÷Ëæ×Å·à±ãÖÐÒÒËá¡¢±ûËáºÍ¶¡Ëáˮƽ½µµÍ¼°Ñª½¬ÖбûËá¡¢¶¡ËáºÍÎìËáˮƽÔöÌí£¬AUCÕ¹Íû׼ȷ¶ÈÌá¸ß£¨Í¼3A£©¡£±ðµÄ£¬½«·à±ãºÍѪ½¬ÖÐSCFAsˮƽÓëÔ˶¯ÕÏ°ÑÏÖØˮƽ×ö¹ØÁªÆÊÎö£¬·¢Ã÷·à±ãÖÐÒÒËá¡¢±ûËáºÍ¶¡ËáµÄˮƽÓëÔ˶¯ÄÜÁ¦³Ê¸ºÏà¹Ø¡£
ͼ3.PD»¼ÕßÓë±ÈÕÕ×éµÄROCÆÊÎö¼°PD»¼ÕßÖÐSCFAsˮƽÓëÁÙ´²Ô˶¯Ö¢×´ÑÏÖØˮƽ֮¼äµÄÏà¹ØÐÔ
ÈÏÖªÕý³£µÄPD»¼Õߺͻ¼ÓгմôÖ¢µÄPD(Parkinson Disease Dementia, PDD)»¼ÕßµÄSCFAs²î±ðÆÊÎöÏÔʾ£¬Ñª½¬ÖУ¬PDD»¼ÕßѪ½¬ÖÐÒ춡ËáºÍÎìËáˮƽÏÔÖøÉý¸ß£¨Í¼4B)£¬ÕâÅúעѪ½¬Ò춡ËáºÍÎìËáˮƽÓëÈÏÖªÄÜÁ¦³Ê¸ºÏà¹Ø¡£
ͼ4.²î±ðÈÏÖªÑÏÖØˮƽµÄPD»¼Õß·à±ãºÍѪ½¬ÖÐSCFAsŨ¶ÈµÄ½ÏÁ¿¼°SCFAsˮƽÓëÈÏÖªÄÜÁ¦Ö®¼äµÄÏà¹ØÐÔ
ºê»ùÒò×éÆÊÎöÅú×¢£¬PD»¼ÕߵľúȺ¸»ºñ¶È¸ßÓÚ±ÈÕÕ×飨ͼ5£©¡£½øÒ»²½ÆÊÎö³¦µÀ¾úȺÓëSCFAsµÄÏà¹ØÐÔ£¬Ð§¹ûÅú×¢£¬ÔÚPD»¼ÕßÖУ¬Ò»Ð©Ìض¨³¦µÀ΢ÉúÎïȺºÍPD»¼ÕßÔ˶¯»òÈÏÖªÕÏ°ÑÏÖØˮƽÏà¹ØµÄSCFA¾ßÓÐÏà¹ØÐÔ¡£
? ²Î¿¼ÎÄÏ×
Chen Szu-Ju,Chen Chieh-Chang,Liao Hsin-Yu et al. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients.[J] .Neurology, 2022.